2BO
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more
2BO (2BO) - Net Assets
Latest net assets as of September 2025: €1.59 Million EUR
Based on the latest financial reports, 2BO (2BO) has net assets worth €1.59 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€12.41 Million) and total liabilities (€10.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.59 Million |
| % of Total Assets | 12.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
2BO - Net Assets Trend (2021–2024)
This chart illustrates how 2BO's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 2BO (2021–2024)
The table below shows the annual net assets of 2BO from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €508.00K | +101.57% |
| 2023-12-31 | €-32.29 Million | +14.52% |
| 2022-12-31 | €-37.78 Million | -7.61% |
| 2021-12-31 | €-35.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 2BO's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 855362600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €44.96 Million | 7013.88% |
| Total Equity | €641.00K | 100.00% |
2BO Competitors by Market Cap
The table below lists competitors of 2BO ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kanoria Chemicals & Industries Limited
NSE:KANORICHEM
|
$6.24 Million |
|
Electric Royalties Ltd
OTCQB:ELECF
|
$6.24 Million |
|
Mountain Alliance AG
XETRA:ECF
|
$6.24 Million |
|
Strong Petrochemical Holdings Limited
F:K20A
|
$6.24 Million |
|
Jeju Beer Co. Ltd.
KQ:276730
|
$6.23 Million |
|
Natural Capsules Limited
NSE:NATCAPSUQ
|
$6.23 Million |
|
AIM ImmunoTech Inc
NYSE MKT:AIM
|
$6.23 Million |
|
Zhong Yang Financial Group Limited Ordinary Shares
NASDAQ:TOP
|
$6.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 2BO's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -32,294,000 to 641,000, a change of 32,935,000.
- Net loss of 11,141,000 reduced equity.
- New share issuances of 5,000,000 increased equity.
- Other factors increased equity by 39,076,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-11.14 Million | -1738.07% |
| Share Issuances | €5.00 Million | +780.03% |
| Other Changes | €39.08 Million | +6096.1% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares 2BO's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 17.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-4.17 | €1.17 | x |
| 2022-12-31 | €-4.49 | €1.17 | x |
| 2023-12-31 | €-3.84 | €1.17 | x |
| 2024-12-31 | €0.07 | €1.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 2BO utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1738.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19894.64%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 10.49x
- Recent ROE (-1738.07%) is below the historical average (-434.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -36.50% | 1.88x | 0.00x | €2.25 Million |
| 2022 | 0.00% | -453.44% | 0.69x | 0.00x | €1.10 Million |
| 2023 | 0.00% | 167.11% | 0.35x | 0.00x | €8.50 Million |
| 2024 | -1738.07% | -19894.64% | 0.01x | 10.49x | €-11.21 Million |
Industry Comparison
This section compares 2BO's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,438,735,438
- Average return on equity (ROE) among peers: -27.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 2BO (2BO) | €1.59 Million | 0.00% | 6.79x | $6.23 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |